Introduction
Mutations in the ALS5/SPG11/KIAA1840 gene, located on chromosome 15q21.1, cause autosomal recessive hereditary spastic paraplegia (ARHSP; OMIM #604360), frequently associated with thin corpus callosum and axonal peripheral neuropathy (Stevanin et al., 2007a, b; Lo Giudice et al., 2014) , as well as autosomal recessive juvenile amyotrophic lateral sclerosis (ARJALS; OMIM %602099), characterized by slowly progressive spasticity of limb and facial muscles with distal amyotrophy of hands and feet (Orlacchio et al., 2010) . Charcot-Marie-Tooth (CMT) disease is a hereditary peripheral neuropathy characterized by slowly progressive distal muscle weakness, atrophy, and mild sensory loss, primarily in lower limbs. It is the most common degenerative disorder of the peripheral nervous system, with a global prevalence of 1 in 2500 (Tazir et al., 2013) . Phenotypes are grouped within the hereditary motor and sensory neuropathies (HMSNs; Dyck and Thomas, 2005) and can be divided into demyelinating (CMT1), axonal (CMT2), and intermediate forms, on the basis of electrophysiological criteria as well as pathological features (Dyck et al., 1968) . In CMT2, peripheral nerves are neither enlarged nor hypertrophic, with normal or near-normal conduction velocities; the disease course is highly variable, ranging from mild to severe forms (Feely et al., 2011; Tazir et al., 2014) . The subtypes belonging to ARCMT2 share common and distinctive clinical features, e.g. CMT2B2 is characterized by sensory deficits, whereas CMT2K is characterized by hoarse voice and vocal cord paresis (Claramunt et al., 2005; Leal et al., 2009) . To date, ARCMT2 has been associated with mutations in only a few genes, and many forms are still unrecognized (Bird, 1993 (Bird, -2015 . Recent advances in the molecular genetics of Charcot-Marie-Tooth disease have contributed to the classification and diagnosis of this heterogeneous disease (Jerath and Shy, 2015) .
The overlap between CMT2 and hereditary spastic paraplegia (Timmerman et al., 2013; Fridman and Murphy, 2014) , as well as the fact that the ALS5/SPG11/ KIAA1840 gene product (spatacsin) is implicated in axonal maintenance and cargo trafficking (Pérez-Brangulí et al., 2014) , and the common autosomal recessive inherited findings of thin corpus callosum and CMT2 in three related patients, motivated us to investigate the ALS5/SPG11/KIAA1840 gene in families with ARCMT2 with no causative gene identified.
Materials and methods

Patients
This study was performed according to a protocol reviewed and approved by the Ethics Committee of the Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia, Rome, Italy. After obtaining informed consent, patients were recruited by a network of neurologists in Italy, Brazil, Canada, England, and Japan, with a significant background in peripheral neuropathy.
The study focused on 28 unrelated pedigrees with ARCMT2 and without genetic assessment. The diagnosis of ARCMT2 was based on neurological findings, familial history, along with neurophysiological characteristics (Bird, 1993 (Bird, -2015 . Flexor and extensor muscle strength was assessed manually using the standard Medical Research Council Scale (Medical Research Council, 1981) . The Functional Disability Scale and the Charcot-Marie-Tooth Neuropathy Score assessed the staging of the disease (Birouk et al., 1997; Murphy et al., 2011) .
All affected subjects under the age of 18 were investigated for IQ through the Wechsler Intelligence Scales for Children IV, including the Wechsler Memory Scale (http://alpha.fdu.edu/ps ychology/WISCIV_Index.htm). According to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association, 2013), mental retardation was considered when the IQ was 470 before the age of 18. Adults were evaluated by Mental Deterioration Battery (Carlesimo et al., 1996) to assess cognitive impairment. Brain MRI was obtained in all affected individuals, with the exception of eight subjects. Haematological and biochemical profiles, as well as lysosomal enzyme assay of b-hexosaminidase A and B in peripheral blood leucocytes, were performed in at least one patient within each family. CSF analysis was available in 21 patients. Vitamins B 1 , B 2 , B 6 , B 9 , B 12 , and E were measured in all patients.
Nerve conduction study was carried out with a surface skin temperature between 32 C and 34 C. Nerves were analysed bilaterally in upper and lower limbs using percutaneous stimulation and surface recording electrodes. Concentric needle EMG was performed in muscles of upper and lower limbs: spontaneous activity, duration, and amplitude of motor unit action potentials, as well as motor unit action potentials, interference pattern during maximal voluntary contraction, were recorded. Sural nerve biopsy was available in 25 patients. Light microscopy preparations, and the electron microscopic analysis in one patient, were performed according to standard methods (Palumbo et al., 2002) .
Genetic analyses
Genomic DNA was extracted from peripheral blood using the Promega Wizard Õ Genomic DNA isolation kit. Linkage study of the 28 families with ARCMT2 was performed using microsatellite markers flanking the ALS5/SPG11 locus, as previously described (Orlacchio et al., 2010) . In the probands, all the coding exons of ALS5/SPG11/KIAA1840 and at least 50 bp of flanking intronic sequence were PCR-amplified by primer pairs, as previously described (Stevanin et al., 2007a) , and by Roche FastStart TM PCR Master Mix polymerase. All the PCR-amplified products were purified using a Qiagen PCR purification kit. Purified products were sequenced with respective forward and reverse primers by an Applied Biosystems 3130 Genetic Analyzer. Sequence analysis was performed using SeqScape software (v2.6; Applied Biosystems). Large genomic rearrangements of ALS5/SPG11/KIAA1840 gene were investigated by multiplex ligation-dependent probe amplification method with the P306-B1 SPG11 probe mix, containing probes for each of the 40 KIAA1840 exons. Data were collected and analysed with GeneScan software (v.3.1.2; Applied Biosystems). For each sample, peak areas were calculated and compared with three wild-type controls, using Coffalyser software (v.7.0; MRC Holland).
The segregation analysis within the family and the surveillance of mutations in the control population were performed using a PCR-restriction fragment length polymorphism method. Three hundred control chromosomes were obtained from healthy volunteers of mixed ethnic origins, including Caucasian, Brazilian and Japanese.
An in silico pathogenicity prediction tool (Mutation Taster, http:www.mutationtaster.org) was used to predict the effect of the novel mutations identified, as previously described (Carosi et al., 2015) .
In all probands, we performed direct sequencing of all exons and flanking introns of CMT2A2/HMSN2A2/MFN2 (OMIM: #609260; Nicholson et al., 2008) Nishino et al., 2000) genes was also carried out to exclude mitochondrial disorders related to CMT2 (Cassereau et al., 2014) . Furthermore, linkage to chromosome 8q13-21.1 was performed to investigate autosomal recessive CMT2H, as previously reported (Barhoumi et al., 2001) .
Results
Genetic findings
Linkage analysis in 28 unrelated pedigrees with ARCMT2 highlighted homozygous haplotypes with positive logarithm of odds score in all affected subjects from consanguineous parents of nine families (Families RM-501, RM-588, RM-603, RM-626, SP-012, SP-026, TOR-018, TOR-029 and TK-031), showing a cumulative two-point logarithm of odds score of 11.76 at the recombination fraction = 0.0 for marker D15S537 (Fig. 1) . The other ARCMT2 families showed heterozygous haplotypes and three of these kindred (Families RM-801, RM-888, and CAM-006) had positive logarithm of odds score in all affected individuals, showing a cumulative two-point logarithm of odds score of 6.29 at the recombination fraction = 0.0 for marker D15S537 (Fig. 1) . All other ARCMT2 pedigrees with heterozygous haplotypes had a negative or borderline significant cumulative logarithm of odds score by the genetic program HOMOG (Ott, 1983) .
We detected 15 different ALS5/SPG11/KIAA1840 mutations in 29 affected individuals from 12 of 28 unrelated families with ARCMT2 (Table 1) . Nine of these nucleotide changes were homozygous and six others, detected in the affected subjects of Families RM-801, RM-888 and CAM-006, were heterozygous compounds. All variants but one were truncating, including eight frameshift mutations, and six nonsense mutations. One nucleotide change (p.Arg945Gly) was a missense mutation. Variants segregated with the disease in all pedigrees and were absent in the panel of control chromosomes. Thirteen mutations had already been reported, while two (p.Gln198* and p.Pro2212Serfs*5) were novel and segregated with the disease (Table 1 and Fig. 2 ). Their pathogenic effect was predicted by bioinformatics analysis. In these families, the ALS5/SPG11/KIAA1840 gene had no large deletions/duplications. Genetic analysis of the other candidate genes (CMT2A2/ HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/ GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/ IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT, GAN/GAN, SPG7/PGN, SPG15/ ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG56/CYP2U1, and SLC12A6) did not reveal any coding mutations in the unrelated 28 families with ARCMT2. Direct sequencing of POLG and TYMP genes excluded mitochondrial disorders related to CMT2. Linkage analysis showed no linkage to chromosome 8q13-21.1 in all families (cumulative logarithm of odds score was À2.11 for marker D15S537 at = 0.0).
Clinical findings of the ALS5/SPG11/ KIAA1840-related ARCMT2 families
Among the 12 ALS5/SPG11/KIAA1840 mutated pedigrees, nine showed consanguinity marriage (first-degree cousins) in their parents. Six families were from Italy, two from Brazil, one from England, and one from Japan.
Moreover, two families were from Canada, one of which was an Iranian family who emigrated to Ontario (Fig. 1) .
Affected subjects had a mainly distal, slowly progressive sensory and motor axonal neuropathy. The age at onset of the first motor symptoms in the 29 mutated ALS5/SPG11/ KIAA1840 patients oscillated from 4 to 35, with a mean of 11.4 AE 5.9 years. The mean age at examination was 25.1 AE 7.8 years (range 9-52).
A wide variation of phenotypic expression was detected (Table 2) . Asymmetrical onset in lower limbs was present in 12 patients. Distal lower limb weakness was found in all affected individuals; 16 patients showed muscular weakness in upper limbs too. Wasting was frequent in lower limb muscles distally (69%) and in intrinsic hand muscles (48%). Lower limb fasciculations were detected in eight patients. No patient showed pontobulbar signs, such as jaw spasticity, poor palatal elevation, increased facial reflexes, masseter, pterygoids, sternocleidomastoid, tongue muscle weakness, or muscle atrophy with fasciculations. Four patients had proximal lower limb weakness. Loss of pinprick and light touch sensation was common and involved lower limbs in most cases (86%).
The most frequent additional signs were foot deformities (79%), mainly pes cavus and kyphoscoliosis (59%). Hand deformities were present in seven patients with longer disease duration. Ankle contracture was present in 14 patients (48%) and tremor in 10 (34%). Bladder disturbances and sexual dysfunctions were detected in about one-third of the affected subjects. Babinski's sign was present bilaterally in two unrelated patients. No affected subject showed cerebellar signs or retinal disease.
Brain MRI images were available for all mutated KIAA1840 patients. Thin corpus callosum was evident in the three affected siblings of Family RM-801, with severe thinning of the anterior portion and mild thinning of the splenium (Fig. 3A) . These patients had low scores in the Wechsler Intelligence Scales for Children IV Intelligence Quotient (ID 7958: 51, ID 7983: 49, and ID 7995: 62; at 13, 11, and 9 years, respectively) with poor school performance and deficit in memory and calculation tests. Normal corpus callosum and no mental retardation or cognitive deficits were observed in the other ARCMT2 KIAA1840-mutated subjects.
Haematological and biochemical profiles, including serum creatine kinase, were unremarkable in all subjects. Lysosomal enzyme assay of peripheral blood leucocytes revealed that both b-hexosaminidase A and B isoenzymes were present at normal levels. Vitamins were within normal range. The CSF analysis was within normal range in the five patients analysed.
The disease was slowly progressive and most patients (86%) expressed mild-to-moderate phenotypes (CharcotMarie-Tooth neuropathy score 5 20); only two patients, one of which was wheelchair bound, reached Functional Disability Scale scores 4 5 ( Table 2) .
Motor and sensory conduction studies showed motor and sensory axonal neuropathy, more prominent in lower limbs, with low amplitudes of compound motor and sensory nerve action potentials. Motor and sensory nerve conduction velocities were normal or slightly reduced, according to the secondary demyelinating processes. All motor nerve conduction velocities of median nerves were 438 m/s, differentiating CMT2 from CMT1. In 29 affected individuals, EMG of the tibialis anterior muscle detected predominant findings of chronic denervation/reinnervation (motor unit action potentials with long duration and large amplitude, or polyphasic, along with single or mixed interference patterns), and/or active denervation signs (fibrillation potentials, positive sharp waves, as well as fasciculation potentials). In 11 affected subjects, EMG of the abductor pollicis brevis muscle showed similar neurophysiological characteristics (Table 3) .
Neuropathological analyses of the sural nerve biopsies were performed in 17 mutated patients and showed loss of myelinated fibres (Fig. 4A) , mainly in fibres of large calibre, in line with the diagnosis of CMT2.
See the online Supplementary material for indicative case reports of patients with novel ALS5/SPG11/KIAA1840 mutations.
Discussion
The ALS5/SPG11/KIAA1840 gene was analysed in ARCMT2 patients from 28 unrelated pedigrees and a high frequency of pathogenic mutations, two of which were novel, was found in 12 families (43%), appearing to be a significant cause of ARCMT2. Our study showed Gene nucleotide numbering was based on the reference sequence NM_025137.3, with the A of the ATG start codon as position 1. del = deletion; fs = frameshift; ins = insertion; M = motor; SM = sensorimotor; RFLP = restriction fragment length polymorphism. novel genotype-phenotype correlation, which further broadens the clinical spectrum associated with ALS5/SPG11/ KIAA1840 mutations (Fig. 5) . Therefore, genetic screening of the ALS5/SPG11/KIAA1840 gene should be considered not only in patients with ARHSP with thin corpus callosum and in affected individuals with ARJALS, but also in affected subjects with ARCMT2. Due to the complexity and heterogeneity of these neurodegenerative diseases, next-generation sequencing techniques are the most effective diagnostic tool to identify the genetic cause in patients with myelopathy or neuropathy, either by targeted sequencing panel approach or by whole-genome sequencing.
This clinical-genetic entity shows a worldwide distribution, since the pedigrees carrying mutations in ALS5/ SPG11/KIAA1840 were from Italy, Brazil, Canada, England, Iran, and Japan. The variants are scattered throughout the entire amino acid sequence, without evidence of 'hot spots', and 93% were truncating mutations. This finding is consistent with previous studies describing mostly mutations leading to the truncation of the ALS5/ SPG11 protein and consequent loss of function mechanism (Pensato et al., 2014) . Furthermore, a probable mechanism of nonsense-mediated mRNA decay might also be hypothesized (Paisan-Ruiz et al., 2008) .
The two unrelated ARCMT2 patients with bilateral Babinski's sign further enlarge the clinical spectrum of the disorder, showing that KIAA1840-related diseases might be clinically suspected if neuropathy is present in addition to (ID 8753, ID 8762, and ID 8780) , and heterozygous status in the relatives (ID 8740, ID 8745, and ID 8752) . (C) PCR-restriction fragment length polymorphism assays. After BsgI digestion, heterozygous individuals of Family RM-801 show three bands at 540, 351, and 189 base pairs (bp), while wild-type subjects display two bands at 351 and 189 bp (I). AseI digestion proves one band in wild-type components at 248 bp, as well as two bands at 273 and 248 bp in mutated individuals (II). Cfr10I digestion (c.6632dupG) leads to three bands at 268, 157, and 111 bp in heterozygous samples and one band at 268 bp (uncleaved) in wild-type components of Family RM-888 (III). Assay with enzyme Cac8I displays one band in wild-type individuals at 228 bp, as well as two bands at 260 and 228 bp in mutated subjects (IV). Wt = wild-type; Htz = heterozygous; Mut = mutated.
upper motor neuron signs or symptoms, e.g. deep tendon reflexes are symmetrically diminished in the lower extremities with bilateral positive Babinski's sign. Moreover, the impairment of higher mental functions impairment and brain alterations at MRI in three affected siblings of one ARCMT2 family should be noted. Indeed, the presence of clinical signs of leukoencephalopathy, as well as white matter alterations at brain MRI, has been previously reported in demyelinating, axonal, and intermediate forms of the disorder (Genari et al., 2011; Reyes-Marin et al., 2011; Sagnelli et al., 2014) . Therefore, we believe that brain MRI and neuropsychological testing are useful tools in the clinical work-up of patients with Charcot-MarieTooth disease. To our knowledge, this is the first report of ALS5/SPG11/KIAA1840 mutations in subjects with ARCMT2 and all of our families can be classified as CMT2X, according to the classification of the CharcotMarie-Tooth disease currently used in OMIM (http:// www.ncbi.nlm.nih.gov/omim).
The disease has a slow progression and affected subjects with earlier onset show a more severe phenotype compared to those with late onset. Overall, the age at onset is the second decade of life, in line with both ARCMT2 and ARHSP (Tazir et al., 2013; Lo Giudice et al., 2014) . Clinical heterogeneity is well documented in ALS5/SPG11/ KIAA1840 mutations causing ARHSP, ranging from the most frequent association of thin corpus callosum, white matter alterations, mental retardation, cerebellar signs, and axonal peripheral neuropathy, to less common clinical findings, such as seizures, abnormal eye signs, maculopathy, amyotrophy, and parkinsonism (Tessa et al., 2014) . In addition, ALS5/SPG11/KIAA1840 mutations have been often found in patients with ARJALS (Orlacchio et al., 2010) . Interestingly, no specific differences in the type of variants, or position within the primary amino acid sequence, were observed. Even identical mutations causing different phenotypes were found (Fig. 5) , confirming that variants at the same locus can lead to distinct phenotypes (Hegele, 2005) . This aspect is not uncommon in monogenic diseases and demonstrates how genotype-phenotype associations can be often unpredictable.
The complexity of a correct clinical classification of motor neuron diseases linked to spatacsin is further increased by the presence of ALS5/SPG11/KIAA1840 mutations in patients with an overlapping phenotype, exhibiting features of amyotrophic lateral sclerosis as well as spastic paraplegia, as described by Querin et al. (2014) .
As previously hypothesized, the ALS5/SPG11/KIAA1840 phenotype results from the combined degeneration of central and peripheral axons (Hehr et al., 2007) . In particular, peripheral neuropathy might affect both sensory and motor fibres and might lead to pure distal amyotrophy, as well as to CMT2. The roles of spatacsin in the cellular pathway of axonal maintenance, including cargo trafficking, is becoming clearer: it is located in axons and dendrites, co-localized with cytoskeletal and synaptic vesicles, and it is present in synaptosomes (Chiurchiù et al., 2014; Pérez-Brangulí et al., Age at onset was calculated as the time when motor symptoms appeared. FDS (Functional Disability Scale) from 0 to 8 as follows: 0 = normal; 1 = normal, but with cramps and fatigability; 2 = inability to run; 3 = walking difficult, but still possible unaided; 4 = able to walk with a cane; 5 = able to walk with crutches; 6 = able to walk with a walker; 7 = wheelchair bound; 8 = bedridden. CMTNS = Charcot-Marie-Tooth Neuropathy Score: mild (410), moderate (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , and severe (420). *Ages at onset were 4 and 9 years; # ages at onset were 4, 8, 9, and 12 years. -TA muscle  ----29  23  8  APB muscle  ----11  9  3 APB = abductor pollicis brevis; CMAP = compound nervous motor action potential (amplitude); MNCV = motor nerve conduction velocity; SD = standard deviation; SNAP = sensory nerve action potential (amplitude); SNCV = sensory nerve conduction velocity; TA = tibialis anterior; UR = unrecordable (action potentials). a Reference lower value is the lower limit assessed by our laboratories; b
The 'Pathological' column includes non-recordable items; c Orthodromic evaluation. *SNAP reference lower value of sural nerve is calculated as: 11.34 À (0.092 Â age in years) À 5.04 mV (Bienfait, 2007) . 2014). Other forms of hereditary spastic paraplegia linked to proteins involved in axon maintenance, such as kinesin SPG10/KIF5A and SPG17/BSCL2, are known to be allelic to CMT2 (Goizet et al., 2009; Ito and Suzuki, 2009; Crimella et al., 2012; Timmerman et al., 2013) . Furthermore, mutations in SPG4/SPAST, SPG3A/ATL1, SPG17/BSCL2, as well as SPG43/C19orf12 might cause spastic paraplegia and axonal peripheral neuropathy with atrophy of small hand muscles (Silver syndrome) (Windpassinger et al., 2004; Orlacchio et al., 2008; Fusco et al., 2010; Landouré et al., 2013) . Besides, mutations in ATL1, whose protein is implicated in neurite outgrowth, intracellular membrane trafficking, and axon elongation during neuronal development (Byrnes and Sondermann, 2011) , might cause hereditary sensory neuropathy type I (HSN-I) with or without pyramidal tract features (Guelly et al., 2011; Leonardis et al., 2012) .
Remarkably, the previously reported mutations in ALS5/ SPG11/KIAA1840 were often associated with ARHSP complicated by axonal peripheral neuropathy, mainly motor, but also sensory (Table 1) . In KIAA1840 mutations, a preferential involvement of the CNS or the peripheral nervous system may be due to different causes. First of all, the blood-nerve barrier might influence protein expression in peripheral axons, as well as the blood-brain barrier in central axons. Moreover, ALS5/SPG11/KIAA1840 knockdown in Zebrafish (Danio rerio) reveals a compromised outgrowth of spinal motor axons, thus indicating that spatacsin is involved in the formation of neuromuscular junctions during development (Martin et al., 2012) . The association in synaptosomes of spatacsin with spastizin (SPG15/ZFYVE26) and with the adaptor protein complex 5 (SPG48/KIAA0415) (Hirst et al., 2013) suggests that the loss of function of spatacsin could not be the only mechanism for axonal dysfunction in ALS5/SPG11/KIAA1840-mutated patients. Indeed, it may be hypothesized that a variable phenotypic expression of KIAA1840 mutations results from the interaction of gene modifier factors. Further studies are necessary to clarify whether allelic heterogeneity depends on environmental or other genetic/epigenetic factors. In conclusion, the presence of common molecular, pathological, and genetic features in KIAA1840-related diseases, suggests that the different phenotypes of axonal degeneration induced by ALS5/SPG11/KIAA1840 mutations may be targeted by common therapeutic strategies.
